Centessa Pharmaceuticals PLC Sponsored ADR $CNTA Holdings Trimmed by SummitTX Capital L.P.

SummitTX Capital L.P. lessened its holdings in shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) by 37.8% during the 1st quarter, HoldingsChannel reports. The fund owned 206,847 shares of the company’s stock after selling 125,861 shares during the period. SummitTX Capital L.P.’s holdings in Centessa Pharmaceuticals were worth $8,216,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. TD Waterhouse Canada Inc. bought a new position in Centessa Pharmaceuticals during the fourth quarter valued at about $25,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of Centessa Pharmaceuticals in the fourth quarter valued at approximately $36,000. T. Rowe Price Investment Management Inc. grew its stake in shares of Centessa Pharmaceuticals by 7,580.0% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,536 shares of the company’s stock worth $39,000 after acquiring an additional 1,516 shares during the last quarter. Wells Fargo & Company MN increased its position in Centessa Pharmaceuticals by 42.4% during the fourth quarter. Wells Fargo & Company MN now owns 3,387 shares of the company’s stock worth $85,000 after acquiring an additional 1,008 shares during the period. Finally, Knott David M Jr bought a new position in Centessa Pharmaceuticals during the fourth quarter worth $100,000. Institutional investors and hedge funds own 82.01% of the company’s stock.

Centessa Pharmaceuticals Stock Performance

NASDAQ:CNTA opened at $40.50 on Monday. Centessa Pharmaceuticals PLC Sponsored ADR has a 12-month low of $12.74 and a 12-month high of $40.56. The company has a quick ratio of 9.53, a current ratio of 9.53 and a debt-to-equity ratio of 0.23. The firm has a market capitalization of $6.27 billion, a PE ratio of -22.63 and a beta of 1.11. The firm has a 50-day moving average price of $40.14 and a 200 day moving average price of $33.76.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.14). Research analysts anticipate that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

CNTA has been the subject of a number of research reports. Guggenheim downgraded shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, April 2nd. Wells Fargo & Company cut shares of Centessa Pharmaceuticals from an “overweight” rating to an “equal weight” rating and increased their target price for the company from $35.00 to $42.00 in a research note on Monday, April 20th. Needham & Company LLC downgraded Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, March 31st. Leerink Partners lowered Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating and boosted their price target for the company from $36.00 to $40.00 in a research note on Wednesday, April 1st. Finally, Truist Financial cut Centessa Pharmaceuticals from a “buy” rating to a “hold” rating and set a $38.00 price target for the company. in a report on Monday, April 13th. Four equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $41.33.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.